Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

BACKGROUND: Metastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased the cos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungari, Andrea Queiróz, Pereira, Leonardo Régis Leira, Nunes, Altacílio Aparecido, Peria, Fernanda Maris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645838/
https://www.ncbi.nlm.nih.gov/pubmed/29041915
http://dx.doi.org/10.1186/s12885-017-3679-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5645838/
https://www.ncbi.nlm.nih.gov/pubmed/29041915
http://dx.doi.org/10.1186/s12885-017-3679-5

Ejemplares similares